While our study supports the feasibility of a response-guided approach for HER2-positive breast cancer in the neoadjuvant setting, we were unable to identify specific clinicopathological factors that could reliably predict which patients would benefit from the addition of pyrotinib to trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.